Dr Mark Kris continues his discussion on neoadjuvant vs adjuvant therapy for locally advanced lung cancer, offering his take ...

Circulogene today announced the national launch of OncoGenDx, an innovative tissue-based comprehensive genomic profiling (CGP ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

In a breakthrough cancer therapy development, scientists at MIT and Harvard Medical School created a new way of designing ...

Observational studies or clinical trials reporting tissue-based PD-L1 expression by Tumor Proportional Score/Combined Positive Score using immunohistochemistry were included. Clinical trials of BTC ...

The efficacy of molecule-matched treatment on hyperprogressive disease after immunotherapy: A retrospective study from the Molecular Tumor Board registry. This is an ASCO Meeting Abstract from the ...

Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to ...

CCR5 inhibition combined with ICI therapy increased overall survival in patients with mTNBC, with 18% of heavily pretreated mTNBC patients alive after a median of ~60 months. Inhibition of CCR5 by ...